A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study

References

• AhrénBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes Obes Metab201113977578321507182
   PubMed Web of Science ®Google Scholar
• AhrénBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab20099441236124319174497
   PubMed Web of Science ®Google Scholar
• FarngrenJPerssonMSchweizerAFoleyJEAhrénBGlucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetesDiabetes Obes Metab Epub2262014
   PubMed Web of Science ®Google Scholar
• FarngrenJPerssonMSchweizerAFoleyJEAhrénBVildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetesJ Clin Endocrinol Metab201297103799380622855332
   PubMed Web of Science ®Google Scholar
• ChristensenMVedtofteLHolstJJVilsbøllTKnopFKGlucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humansDiabetes201160123103310921984584
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJEShaoQKothnyWClinical experience with vildagliptin in the management of type 2 diabetes in a patient population $75 years: a pooled analysis from a database of clinical trialsDiabetes Obes Metab2011131556421114604
   PubMed Web of Science ®Google Scholar
• Al-AroujMAssaad-KhalilSBuseJRecommendations for management of diabetes during Ramadan: update 2010Diabetes Care20103381895190220668157
   PubMed Web of Science ®Google Scholar
• SaltiIBénardEDetournayBEPIDIAR study groupA population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) studyDiabetes Care200427102306231115451892
   PubMed Web of Science ®Google Scholar
• AravindSRAl TayebKIsmailSB2009 Ramadan Study GroupHypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational studyCurr Med Res Opin20112761237124221506631
   PubMed Web of Science ®Google Scholar
• SchernthanerGGrimaldiADi MarioUGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsEur J Clin Invest200434853554215305887
   PubMed Web of Science ®Google Scholar
• TayekJSUR receptor activity vs incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabeticsDiabetes Obes Metab200810111128112918671799
   PubMed Web of Science ®Google Scholar
• SchweizerAHalimiSDejagerSExperience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during RamadanVasc Health Risk Manag201410152424391442
   PubMedGoogle Scholar
• HassaneinMHanifWMalikWComparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR studyCurr Med Res Opin20112771367137421568833
   PubMed Web of Science ®Google Scholar
• Al-AroujMHassounAAMedlejRThe effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE studyInt J Clin Pract2013671095796324001317
   PubMed Web of Science ®Google Scholar
• BravisVHuiESalihSMeharSHassaneinMDevendraDRamadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during RamadanDiabet Med201027332733120536496
   PubMed Web of Science ®Google Scholar
• DevendraDGohelBBravisVVildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during RamadanInt J Clin Pract200963101446145019678856
   PubMed Web of Science ®Google Scholar
• BolliGBTsalikianEHaymondMWCryerPEGerichJEDefective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactionsJ Clin Invest1984736153215416373827
   PubMed Web of Science ®Google Scholar
• Landstedt-HallinLAdamsonULinsPEOral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab19998493140314510487677
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEFerranniniEChanges in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapyDiabetes Care201033473073220067974
   PubMed Web of Science ®Google Scholar
• LafeuilleMHGrittnerAMGravelJQuality measure attainment in patients with type 2 diabetes mellitusAm J Manag Care201420Suppl 1s5s1524512194
   PubMed Web of Science ®Google Scholar
• Al SifriSBasiounnyAEchtayA2010 Ramadan Study GroupThe incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trialInt J Clin Pract201165111132114021951832
   PubMed Web of Science ®Google Scholar
• AravindSRIsmailSBBalamuruganRHypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic studyCurr Med Res Opin20122881289129622738801
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEvidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab200810111114112418355325
   PubMed Web of Science ®Google Scholar
• MatthewsDRCharbonnelBHHanefeldMBrunettiPSchernthanerGLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes Metab Res Rev200521216717415386821
   PubMed Web of Science ®Google Scholar
• FilozofCGautierJFA comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized studyDiabet Med201027331832620536495
   PubMed Web of Science ®Google Scholar